# Regulatory Skill: Submission Management

## Role
VP Regulatory Affairs

## Regulatory Grounding
- ICH M4: Common Technical Document (CTD)
- ICH M8: eCTD Specification
- 21 CFR 312.23: IND Content and Format
- 21 CFR 601: BLA Requirements
- FDA Guidance: Formal Meetings Between FDA and Sponsors (2009)
- FDA RMAT Designation Guidance
- FDA Breakthrough Therapy Guidance

## Description
Manages regulatory submission lifecycle from pre-IND through BLA. Ensures all submissions comply with eCTD format requirements and contain required content per applicable regulations.

## CTD Module Structure
| Module | Content | Owner |
|--------|---------|-------|
| 1 | Administrative Information (region-specific) | Regulatory Affairs |
| 2.1-2.3 | CTD Table of Contents, Introduction | Regulatory Affairs |
| 2.4 | Nonclinical Overview | Head CMC / Nonclinical |
| 2.5 | Clinical Overview | CMO |
| 2.6 | Nonclinical Written and Tabulated Summaries | Head CMC |
| 2.7 | Clinical Summary (Efficacy, Safety, Biopharmaceutics) | CMO + Head Biostats |
| 3 | Quality (CMC) | Head CMC |
| 4 | Nonclinical Study Reports | Head CMC |
| 5 | Clinical Study Reports | VP Clinical Ops |

## IND Sections Required (21 CFR 312.23)
1. Cover sheet (Form FDA 1571)
2. Table of contents
3. Introductory statement and general investigational plan
4. Investigator's Brochure
5. Protocol(s)
6. Chemistry, Manufacturing, and Control information
7. Pharmacology and Toxicology information
8. Previous human experience
9. Additional information

## Key FDA Meeting Types
| Meeting | Purpose | Timing |
|---------|---------|--------|
| Pre-IND (Type B) | Discuss IND strategy, nonclinical requirements | Before IND |
| End-of-Phase-1 | Discuss Phase 2 design, dose selection | After Phase 1 |
| End-of-Phase-2 (Type B) | Agree on Phase 3 design, endpoints | After Phase 2 |
| Pre-BLA (Type B) | Discuss submission format, outstanding issues | Before BLA |
| Type A | Stalled development, clinical hold, dispute resolution | As needed |

## Expedited Programs
| Program | Criteria | Benefit |
|---------|----------|---------|
| Breakthrough Therapy | Serious condition + preliminary clinical evidence of substantial improvement | Intensive FDA guidance, rolling review |
| RMAT | Regenerative medicine + serious condition + preliminary evidence | Same as Breakthrough + potential accelerated approval |
| Priority Review | Significant improvement in safety/effectiveness | 6-month review (vs 10) |
| Accelerated Approval | Serious condition + surrogate endpoint | Approval based on surrogate, confirmatory trial required |

## Output
- Submission-ready eCTD module structure
- Gap analysis against required content
- Timeline to submission with milestones
- FDA meeting request briefing documents

## Escalation
- Reports to: CEO
- Escalate if: clinical hold, refuse-to-file, complete response letter

## Dashboard
- Tab: Clinical Pipeline (new) â€” submission timeline, milestone tracker, gap analysis
